Group 1 - The core view is that A-shares are expected to outperform Hong Kong stocks in 2026 due to relative advantages in fundamentals and liquidity, while Hong Kong stocks still hold structural appeal [1][34] - A-shares are projected to have an overall profit growth rate of approximately 4%-5% in 2026, compared to about 3% for Hong Kong stocks, driven by differences in sector composition [34][42] - Key sectors for A-shares include technology hardware, manufacturing, and cyclical industries, while Hong Kong stocks are characterized by dividend, internet, innovative pharmaceuticals, and new consumption sectors, which are less favored in the current market [1][42] Group 2 - The strong performance of A-shares at the beginning of the year is attributed to excess liquidity chasing scarce return assets, rather than significant changes in macro fundamentals [2][12] - The market structure has shown that small-cap stocks have significantly outperformed large-cap stocks, continuing the trend from 2025 [2][3] - A-shares have seen record high margin trading balances and daily trading volumes, indicating strong investor interest and liquidity [8][9] Group 3 - Hong Kong stocks have lagged due to a lack of attractive structural opportunities and weaker liquidity, reflecting a deteriorating fundamental outlook [12][15] - The absence of significant foreign capital inflows and the impact of high U.S. Treasury yields have constrained Hong Kong's liquidity environment [17][20] - The IPO market in Hong Kong remains active, with a total of 2,858 million HKD raised in 2025, but the demand for capital is expected to increase further in 2026 [23][24] Group 4 - The historical cross-year effect shows that A-shares tend to perform better than Hong Kong stocks during the spring season, with A-shares averaging a 4.6% increase compared to 0.5% for Hong Kong stocks over the past 20 years [27][28] - The analysis indicates that A-shares have a higher probability of positive returns during the spring season, particularly in sectors like technology and consumer goods [28][29] Group 5 - The liquidity environment for A-shares is expected to benefit from domestic micro liquidity changes, while Hong Kong stocks face multiple constraints [40][41] - The structural characteristics of Hong Kong stocks, such as dividends and innovative sectors, provide unique investment opportunities that are not easily replicated in A-shares [42][46] - The investment strategy should focus on sectors aligned with credit expansion, including AI, dividends, cyclical, and consumption sectors, with A-shares generally having an advantage in technology and cyclical sectors [45][46]

Core Viewpoint - The strong performance of A-shares at the beginning of 2026 is primarily driven by "excess liquidity" chasing "scarce return assets," rather than significant changes in the macroeconomic fundamentals [2][3][5]. Group 1: A-share Market Dynamics - The A-share market has seen a 16-day consecutive rise, with small-cap stocks outperforming large-cap stocks, continuing the trend from 2025 [3][5]. - The main contributors to the A-share gains are valuation expansions, with sectors like commercial aerospace and materials leading the charge [5][8]. - A-share trading volumes have reached historical highs, with a single-day turnover exceeding 30 trillion yuan, indicating strong market activity [5][8]. Group 2: Hong Kong Market Performance - The Hong Kong market has lagged behind, primarily due to a lack of attractive structural opportunities and weaker capital flows [9][11]. - Key sectors in Hong Kong, such as dividends, internet, and new consumption, are not currently in the market's focus, leading to underperformance [11][19]. - The Hong Kong IPO market remains active, with significant fundraising, but the overall market sentiment is subdued compared to A-shares [17][19]. Group 3: Capital Flow and Liquidity - Domestic capital flows have favored A-shares, with southbound capital flows slowing down significantly since late 2025 [15][19]. - The liquidity environment for A-shares is more favorable, benefiting from domestic microeconomic conditions, while Hong Kong faces constraints from external factors [28][30]. - The anticipated inflow of southbound capital in 2026 may not match the record levels seen in 2025, as A-shares attract more attention [30][32]. Group 4: Structural Differences and Future Outlook - A-shares are expected to have a higher overall profit growth rate of 4%-5% in 2026, compared to Hong Kong's 3%, driven by stronger sectors like technology and manufacturing [25][26]. - The structural advantages of Hong Kong, including its focus on dividends and innovative drugs, provide unique investment opportunities, even as A-shares outperform overall [30][32]. - The ongoing credit cycle and its impact on market dynamics will guide investment strategies, with a focus on sectors like AI, dividends, and cyclical stocks [33].

2026年开局，A股市场便迎来了一场"开门红"行情，沪指突破4100点，创下近10年新高，深证成指也突 破14000点，创下近4年新高。两市交易额在1月9日再次突破3万亿元大关。 在这场火热行情的背后，是公募基金等机构资金早已提前"抢跑"布局的身影。证券时报·券商中国记者 采访调研了解到，众多基金经理在2025年四季度末便已悄然提升仓位，精准抓住春季躁动行情，而随着 市场行情回暖，商业航天、半导体芯片、创新药等板块多点开花，10只基金在开年第一周便大涨超 20%，市场赚钱效应显著。 基金"抢跑"春季躁动行情 "我们在去年10月到11月的时候，眼看市场持续缩量震荡，果断执行纪律，基本上把仓位降到了70%， 躲过了一波回调。"近期，一位管理规模超50亿的公募基金经理向证券时报·券商中国记者回顾了他自去 年年底至今的操作。 他坦言，等待市场确认信号的过程是煎熬的，但一些积极因素在去年12月开始出现。"我们观察到一系 列宏观和产业层面的边际变化，比如PMI数据初现企稳迹象、海外流动性预期转向，以及我们重点跟踪 的半导体产业链出现了供不应求的情况，综合判断下，我们认为市场回调得差不多了，于是在去年11月 底到12月份开 ...

Group 1 - In 2025, out of 650 comparable QDII funds, 619 funds saw an increase in net value, representing 95.2% of the total, while 31 funds experienced a decline [1] - The top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed (QDII) A/C, achieved a remarkable growth of 114.19% and 113.83% respectively [1] - The fund's investment strategy focuses on innovative pharmaceuticals with global competitiveness and high-barrier equipment and consumables [1] Group 2 - The current fund manager of Huatai Fuhong is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - Six other QDII funds recorded growth exceeding 80%, with four of them managed by E Fund Management, all surpassing 85% growth [2] - The top holdings of these funds include major companies like TSMC, NVIDIA, Google, and Alibaba [2] Group 3 - There are 26 QDII funds with monthly growth rates between 60% and 80%, with the largest being GF Zhongzheng Hong Kong Innovative Medicine ETF (QDII), which had a growth of 66.65% [3] - The Fuguo Blue Chip Selected Stock (QDII) in USD also showed significant growth of 67.99% [4] Group 4 - The bottom-performing QDII funds in 2025 were primarily those focused on oil and gas products, with 10 funds declining over 10% [5] - E Fund Management had four products leading the decline, with losses ranging from 11.64% to 13.59% [5]

Core Insights - The current A-share market rally is driven by a combination of policy expectations, industry trends, capital flow, and market sentiment, indicating a complex and critical new phase in the market [1][2] - The influx of incremental capital is a key factor in the ongoing market strength, with significant net inflows from northbound capital and increased trading volumes [2][3] Market Dynamics - The strong market performance is attributed to a multi-dimensional resonance of policies, industry developments, and capital dynamics, with a notable shift from a focus on existing capital to new incremental capital [2][3] - Northbound capital has seen multiple days of net inflows exceeding 10 billion yuan since January, with daily trading volumes rising from 1.7 trillion yuan to over 2.8 trillion yuan [2] Investment Strategies - Private equity firms are actively adjusting their portfolios, focusing on both offensive and defensive strategies, with a clear emphasis on sectors like AI and cyclical industries [4][5] - Investment in technology sectors is expanding from hardware to applications, with a focus on areas such as innovative pharmaceuticals, brain-computer interfaces, and commercial aerospace [4][5] Sector Focus - High-growth sectors such as AI applications, commercial aerospace, innovative pharmaceuticals, and non-ferrous metals are repeatedly highlighted as key investment areas [6][7] - There is a growing interest in cyclical assets due to expectations of economic recovery, with private equity firms increasing their holdings in sectors like non-ferrous metals and chemicals [5][6] Investor Sentiment - Institutional investors maintain a strategic optimism, while individual investors exhibit anxiety and indecision, reflecting a dichotomy in market sentiment [4][8] - Recommendations for individual investors emphasize the importance of professional management, focusing on long-term trends, and utilizing standardized investment tools to mitigate selection difficulties [8][9] Conclusion - The current market environment presents a comprehensive test of cognitive depth, strategic flexibility, and investment discipline, with private equity firms adapting their strategies to navigate the complexities of the evolving market landscape [9]

Group 1 - The core viewpoint of the articles indicates that the Hong Kong stock market is facing challenges, particularly in terms of liquidity and performance compared to the A-share market, with a focus on value investment and risk management strategies [1][3][6] - In 2025, the Hong Kong stock market saw significant activity in sectors like innovative drugs and artificial intelligence, but by the end of the year, these sectors experienced a downturn, leading to a lack of high-performing funds in these themes [2][3] - The liquidity issues in the Hong Kong market are characterized by a concentration of trading in large-cap stocks, while small-cap stocks suffer from low trading volumes, leading to a disparity in market performance [3][4] Group 2 - Fund managers emphasize the importance of focusing on fundamental performance and quality of companies when investing in the Hong Kong market, as external factors and macroeconomic conditions heavily influence market dynamics [5][6] - The outlook for the Hong Kong market suggests that sectors such as technology and consumer goods may become key investment themes, with a belief that the market's valuation remains attractive compared to global peers [7][8] - There is a growing interest in high-quality consumer brands and innovative companies within the tea beverage sector, which are expected to achieve stable long-term growth due to their competitive advantages [8]

Group 1 - The core investment logic for public funds in Hong Kong stocks is shifting from chasing market hotspots to deeply exploring internal alpha opportunities within industries as the era of "beta" gains from popular sectors comes to an end [1][2] - The valuation repair of Hong Kong stocks is nearly complete, making it difficult to rely solely on index strategies or betting on hot sectors for sustained success [1][2] - The investment perspective is transitioning from emotion-driven narratives to profit-driven fundamental verification, with a focus on "distilling the truth" becoming key to evaluating research and investment capabilities [1][2] Group 2 - The performance of public funds in Hong Kong stocks is increasingly seen as a test of fund managers' true stock-picking abilities, with the ability to identify companies with sustainable growth and explosive performance becoming crucial [2][4] - The consensus among public funds is that the previous beta-driven market rally is over, and the focus will shift to companies with tangible performance rather than those relying on storytelling [3][4] - Fund managers emphasize the importance of actual performance metrics, such as operating cash flow and successful overseas business development (BD) transactions, as indicators of a company's viability [6][7] Group 3 - The investment strategy is evolving towards a balanced approach, combining growth-oriented investments with high-dividend defensive positions to achieve risk and return balance [8][9] - There is a growing interest in sectors that are currently at the bottom of the cycle, such as consumer stocks, which are seen as having potential for recovery and attractive valuations [8][9] - The focus for 2026 will be on two main areas: AI applications and non-AI growth sectors, as well as the real estate chain, which may present unique investment opportunities [9]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of January 11, 2026 [3] Core Insights - 2025 marked a significant year for Chinese innovative drugs going overseas, with total transaction amounts reaching $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs [4] - The innovative drug index saw a 35.31% increase in 2025, outperforming the CSI 300 index by 17.65% [4] - The trend of Chinese innovative drugs going global is expected to strengthen in 2026, with significant deals such as the one between Yilian Biotech and Roche for the YL201 project, which includes a $570 million upfront payment [4] - The small nucleic acid drug sector is experiencing breakthroughs, with GSK's Bepirovirsen showing positive results in Phase III trials for chronic hepatitis B, potentially becoming the first drug to achieve functional cure [5] - The report highlights the importance of oral autoimmune drugs, with Takeda's TYK2 inhibitor showing promising results in treating moderate to severe plaque psoriasis [6] - The brain-computer interface technology is entering a critical industrialization phase, with companies like Neuralink set to produce devices in 2026, supported by favorable policies and clinical trials in China [8] - The ZAP-X radiotherapy device is expected to capture a significant market opportunity in China, with the non-invasive tumor radiotherapy market projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024 [10] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 2.13% over the past week, ranking 25th among 31 industry indices [28] - Over the past month, the pharmaceutical industry index also lagged behind the CSI 300 by 5.42%, ranking 27th [29] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 36.95, above the five-year historical average of 31.12 [52] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral drugs, and the impact of policy support on the inhalation drug industry [55] 4. Important Industry Policies and News - Recent policies include the issuance of the fourth batch of encouraged generic drug directories by the National Medical Products Administration [57] - Significant news includes GSK's announcement of positive Phase III results for Bepirovirsen and Yilian Biotech's licensing agreement with Roche [58][59]

Core Insights - The report continues to recommend innovative drugs and the related industry chain, highlighting the strong growth potential in the pharmaceutical sector through 2026 [1][4]. Investment Strategy - The investment strategy emphasizes the focus on the CXO sector, particularly in chemical CDMO, where Chinese companies hold significant advantages in talent, chemical capabilities, compliance production, and intellectual property protection [4]. - The report suggests that the upcoming JPM conference will provide updates on the operational progress of Chinese innovative drug companies, which have shown a long-term positive development trend [4]. - The recommended investment portfolio includes A-shares such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, as well as H-shares like Kangfang Biologics and WuXi Biologics [4][5]. Industry Performance - The pharmaceutical industry experienced a decline of 4.10% in December, underperforming the CSI 300 index by 6.38% [8]. - The report notes that the chemical pharmaceutical sector saw the largest declines among sub-sectors, with a drop of 5.80% [12]. Market Data - For the period from January to November 2025, the pharmaceutical manufacturing industry's total revenue was 220.65 billion yuan, reflecting a year-on-year decrease of 2.0% [7]. - The total retail sales of consumer goods reached 45.61 trillion yuan, with retail sales of Western and Chinese medicines amounting to 660.4 billion yuan, a year-on-year increase of 1.8% [7]. Regulatory Environment - The report discusses the impact of the U.S. "Biological Safety Act," which is expected to have a limited short-term effect on Chinese CXO companies, while emphasizing the need to monitor the long-term implications of international competition and regulatory changes [22]. Recent Drug Approvals - In December 2025, a total of 16 innovative drugs or biosimilars were approved for market entry, including six domestic and ten imported products [24][25].